Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:05:05.847Z.
Calculation as of: 2026-10-06T16:05:05.847Z.
Quote observation: 2026-10-06T15:54:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6423558485129ce458f63e69d797580679928a9eb272818a894d3cfd838ee462
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$4.34M
EV/EBITDA Ratio
N/A
TTM Avg
72.60x
3Y Avg
72.60x
5Y Avg
72.60x
Market Cap
$4.64M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.18M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PharmaCyte Biotech, Inc. (PMCB) | $4.45M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.34M | N/A | 72.60x | 72.60x | 72.60x |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.50M | N/A | N/A | N/A | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.23M | N/A | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.64M | N/A | N/A | N/A | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.09M | N/A | N/A | N/A | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.75M | N/A | N/A | N/A | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.79M | N/A | N/A | N/A | N/A |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.18M | N/A | N/A | N/A | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.05M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
